OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (185)	10/16/2002 1:21:10 AM
From: Miljenko Zuanic	Read Replies (2) of 447

Tuck, Similar questions I asked myself. We do not know Iressa PIII tox profile for stage IIIb/IV NSCLC. Side effect profile and IP incidence was from ~200 pts (combination of US and Japan PII trial). Iressa compassionate use count ~10000 pts and so far no word on IP incidence. Also for bit less sick NSCLC (two PIII trials) it was not reported higher IP incidence. Regards the mechanism, so far I can not connect EGF and IP incidence. It can be related to anti-EGF in general, anti-EGF small molecule or Iressa itself???? However, I do believe that this increase in IP incidence and 13 death are in part related to higher Iressa daily dose, which can explain difference from trials and real world. ABGX claim that they did not observed pneumonia in their PI trials, and probably ongoing PII trials. This does not guaranty that they will not have the some problems. Nonetheless, market is acting like this are FACTS (for ABGX and OSIP). Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next